A phase 2 Dana-Farber trial found that all 20 patients with high-risk smoldering multiple myeloma treated with a single infusion of ciltacabtagene autoleucel achieved complete minimal residual disease ...
In contrast, allo-HCT offers the potential for long-term disease control through a graft-vs-tumor effect, in which donor ...
In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...
SurvivorNet on MSN
CELMoDs: The next-generation drugs that could replace Revlimid in myeloma treatment
Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...
It’s a reasonable hope, given the results of that trial, which researchers presented at the American Association for Cancer ...
A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...
Multiple myeloma research led by researchers at the University of Calgary identified how tumor cells adapt after ...
MedPage Today on MSN
CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group
All 20 smoldering myeloma patients had deep responses after one-time infusion ...
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results